Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Automated Extraction System Produces High Quality RNA-free DNA

By LabMedica International staff writers
Posted on 18 Oct 2015
A state-of-the-art precipitation-based system completely automates the DNA extraction process from primary tube sampling to final DNA elution into storage tubes.

The AutoGen (Holliston, MA, USA), FlexSTAR+ platform is a system that produces RNA-free DNA in an extremely user-friendly environment.

The FlexSTAR+ system includes protocols for fresh or frozen blood samples of 1 to 2 milliliters, 3 to 5 milliliters, and 6 to 10 milliliters. More...
The instrument can draw samples from a variety of primary tube sizes, running up to 30 samples in a batch. It reads and records barcodes on primary tubes, has an internal barcode scanner to verify sample input and DNA output positions, provides liquid level detection for accurate pipetting, and delivers its final elution in SBS (sterile barrier system)-type storage tubes of the user’s choosing.

FlexSTAR+ features sample tracking and reporting software that verifies work lists from LIM (laboratory information management) input, creates a map of sample and DNA positions, tracks samples through the extraction process, and sends final reports back to LIMs. The software also sends an email or text alert to notify the operator when the run is complete.

The extraction process operates with Qiagen (Venlo, The Netherlands) FlexiGene chemistry. This precipitation-based procedure yields cleaner, longer-stranded DNA than does magnetic bead-based methods. Furthermore, since the Qiagen DNA extraction process begins with the collection of the white cell nuclei pellet, it eliminates RNA contamination that can occur with magnetic bead technology and other technologies that produce total nucleic acid instead of pure genomic DNA.

“Biorepositories, genetic treatment and cancer centers, and specialty diagnostic labs that currently are using Qiagen’s AutoPure solution for DNA extraction will be familiar and comfortable with precipitation technology,” said Bob Sullivan, president and CEO of AutoGen. “FlexSTAR+ is a logical step-up for them. In fact, it is a superior solution for any lab that wants to generate higher quality, higher yield genomic DNA with less work and errors and far less likelihood of RNA contamination, and that stands to benefit from the superior service for which AutoGen is known.”

Related Links:

AutoGen
Qiagen



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Thyroid Test
Anti-Thyroid EIA Test
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.